Forwarded from @BotMan Baphomet
Telegram
the war between darkness and light
Video from ﷽ََََََََََََََ
Mind control has changed to small parcels such as parasites and viruses from a side of coin and other side vaccine RNA Vehicles and then their control by 5G smart context waves.
when they want then they order and promote viruses…
Mind control has changed to small parcels such as parasites and viruses from a side of coin and other side vaccine RNA Vehicles and then their control by 5G smart context waves.
when they want then they order and promote viruses…
Forwarded from Cherokee Owl 🦉
Media is too big
VIEW IN TELEGRAM
▪️Former VP and Researcher at Pfizer Inc.
▪️Anti-Vaccine activist. 💉🚫
https://news.1rj.ru/str/MichaelYeadonTelegram
🛑 @NonaCoin
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🛑 @Etherway
▪️Anti-Vaccine activist. 💉🚫
https://news.1rj.ru/str/MichaelYeadonTelegram
🛑 @NonaCoin
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🟣🔵🟢🟡🟠🔴
🛑 @Etherway
Forwarded from Google opportunities (@Bot9teen @Botman)
This media is not supported in your browser
VIEW IN TELEGRAM
Forwarded from [P]
Abstract
„The Omicron (B.1.1.529) variant of SARS-CoV-2 was only recently detected in southern Africa, 1 but its subsequent spread has been extensive, both regionally and globally . It is expected to become dominant in the coming 2 weeks, probably due to enhanced transmissibility. A striking feature of this variant is the large number of spike mutations 3 that pose a threat to the efficacy of 4 current COVID-19 vaccines and antibody therapies . This concern is amplified by the findings from our study. We found B.1.1.529 to be markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines. Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529. By
evaluating a panel of monoclonal antibodies to all known epitope clusters on the spike protein,
we noted that the activity of 18 of the 19 antibodies tested were either abolished or impaired, ones currently authorized or approved for use in patients. In addition, we also identified four new spike mutations (S371L, N440K, G446S, and Q493R) that confer greater antibody resistance to B.1.1.529. The Omicron variant presents a serious threat to many existing
COVID-19 vaccines and therapies, compelling the development of new interventions that
anticipate the evolutionary trajectory of SARS-CoV-2.“
https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.full.pdf
@P0P0P1P0
„The Omicron (B.1.1.529) variant of SARS-CoV-2 was only recently detected in southern Africa, 1 but its subsequent spread has been extensive, both regionally and globally . It is expected to become dominant in the coming 2 weeks, probably due to enhanced transmissibility. A striking feature of this variant is the large number of spike mutations 3 that pose a threat to the efficacy of 4 current COVID-19 vaccines and antibody therapies . This concern is amplified by the findings from our study. We found B.1.1.529 to be markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines. Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529. By
evaluating a panel of monoclonal antibodies to all known epitope clusters on the spike protein,
we noted that the activity of 18 of the 19 antibodies tested were either abolished or impaired, ones currently authorized or approved for use in patients. In addition, we also identified four new spike mutations (S371L, N440K, G446S, and Q493R) that confer greater antibody resistance to B.1.1.529. The Omicron variant presents a serious threat to many existing
COVID-19 vaccines and therapies, compelling the development of new interventions that
anticipate the evolutionary trajectory of SARS-CoV-2.“
https://www.biorxiv.org/content/10.1101/2021.12.14.472719v1.full.pdf
@P0P0P1P0